Funda Meric-Bernstam, MD, on Platinum-Resistant Ovarian Cancer: Torvutatug Samrotecan

November 10, 2026

Funda Meric-Bernstam, MD, of The University of Texas MD Anderson Cancer Center, reviews updated results from the FONTANA trial, a phase I/IIa, first-in-human, open-label study, which is evaluating the safety and efficacy of torvutatug samrotecan, a folate receptor α–targeted antibody-drug conjugate, in patients with platinum-resistant ovarian cancer (Abstract 1245RO). 

Related Content